Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from ATAI

These 3 Psychedelic Stocks Activated After Trump's Executive Order

Psychedelic drugs could get a big boost thanks to a recent executive order, and these firms all have promising candidates in line.

MarketBeat

This 4/20, Wall Street Is Betting on More Than Marijuana

Wall Street is currently pivoting toward high-growth biotech plays as federal support accelerates a revolution in alternative medicine.

MarketBeat

High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026

2026 could be a pivotal year for three biotech names, including a standout in the hemodialysis space and two emerging companies with strong pipelines.

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

The 1 Riskiest Investment That Paid Off in 2025

Wall Street still sees triple-digit upside in this high-risk biotech bet.

Barchart

MarketBeat’s Top 5 Rated Small-Cap Stocks

Small-cap stocks are regaining momentum as rate cuts and the end of quantitative tightening drive a renewed risk-on environment.

MarketBeat

North Carolina Wants to ‘Lead the Nation’ in Psychedelics. Here’s 1 ‘Strong Buy’ Stock to Buy Now.

As policy meets potential in North Carolina, Atai Life Sciences could be a solid portfolio addition now.

Barchart

Atai Life Sciences Remains Undervalued, Analyst Initiates With Around 125% Stock Upside

Needham on Monday initiated coverage on Atai Life Sciences NV (NASDAQ:ATAI), a clinical-stage biopharmaceutical company focused on developing treatments for mental health.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Atai Life Sciences Experimental Depression Drug Shows Sustained Benefit In Treatment-Resistant Patients

Atai Life Sciences (NASDAQ:ATAI) and Beckley Psytech Limited, a private clinical-stage biopharmaceutical company, released data from a proof-of-concept study investigating a two-dose induction regimen of BPL-003 (intranasal mebufotenin benzoate) in patients with treatment-resistant depression (TRD).

Benzinga

This Atai Life Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Benzinga

Why Is ATAI Life Sciences Stock Trading Lower On Monday?

Amid a surge in research targeting cognitive disorders, the pharmaceutical industry is witnessing a wave of pivotal trial results that could reshape schizophrenia treatment paradigms. As biotech firms race to develop innovative therapies, Recognify Life Sciences steps into the spotlight with new findings from its latest clinical trial.

Benzinga

Mesoblast, Atai Life Sciences, Melco Resorts & Entertainment And Other Big Stocks Moving Higher On Tuesday

U.S. stocks were mixed, with the Dow Jones index gaining over 250 points on Tuesday.

Benzinga

2 ‘Strong Buy’ Psychedelic Stocks to Scoop Up ASAP

Two psychedelic-focused stocks stand to benefit after the FDA designated psychedelics as a top review priority.

Barchart

A 36-year-old CEO saw how psychedelics treated his best friend’s mental illness. Now his Peter Thiel-funded firm wants to bring the drugs to the masses

Florian Brand's Atai Life Sciences went public three years after launching, fueled by Silicon Valley interest and promising science, but it's still waiting for its first big breakthrough.

Fortune

Atai's New MDMA-Based EMP-01 Compound Moves Forward To The Clinical Stage

Atai Life Sciences' (NASDAQ: ATAI) wholly-owned subsidiary EmpathBio has received Medsafe central regulatory and the Health and Disability Ethics Committees (HDEC) approvals to begin participant enrollment in its Phase 1 trial of proprietary MDMA-based drug EMP-01

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Major Goals For ATAI: $175M Secured In Term Loan Facility, Plus Q2 Earnings Report

Clinical-stage psychedelics company ATAI Life Sciences N.V. (NASDAQ: ATAI) announced its financial results for the quarter ended June 30, 2022 and business updates, including a term loan facility agreement for up to $175 million provided by Hercules Capital Inc.

Benzinga

10 Psychedelics CEOs To Pay Attention To In 2022

By Javier Hasse and Aaron Bry. 2020 and 2021 were defining years for the burgeoning psychedelics industry. In 2021 alone, more than $730 million were invested into various psychedelic companies, both private and public.

Benzinga

atai Life Sciences: Unparalleled Diversification With 10 Psychedelic Compounds Going Into Clinical Trials In 2022

In the speculative world of ‘psychedelic’ biotech, companies that are under-capitalized or lacking pipeline diversity face an uphill battle to reach the finish line.

Benzinga

Psychedelics Atai Life Sciences: Optimizing Drug Development By Avoiding Big Pharma's Past Missteps

In the early days of the psychedelics industry, financial reports mean very little. Unless a company wildly misses its operating spending budget and hemorrhages cash by more than expected, the report is basically a synopsis of a given company’s highlights and milestones over the previous quarter.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Atai Life Sciences Posts Earnings for Q1 2022, Advancing Key Milestones In Psychedelic Drug Development

Atai Life Sciences (NASDAQ: ATAI), a biotech company leading the development of psychedelic compounds for mental health purposes, issued its financial report for the first quarter of the year, ended March 31, 2022.

Benzinga

Psyched: Big Pharma's Sanofi Enters Psychedelics Space, DNA From 80 Psilocybe Mushrooms Published Online, Maine Psychedelics Bill Shelved

Benzinga’s first-ever Psychedelics Capital Conference was a colossal success. Over 600 investors, policymakers, industry executives and thought leaders gathered at the Fontainebleau Hotel in Miami Beach for a full day of networking and education.

Benzinga

EXCLUSIVE: ATAI Life Sciences Deploys Decentralized Approach To Transform Mental Health Treatments

ATAI Life Sciences NV (NASDAQ: ATAI) is deploying a multipronged approach to accelerate the development of mental health treatments.

Benzinga

Christian Angermayer Buys 1 Million Shares Of Atai Life, His Own Company

Christian Angermayer, founder and chairman of Atai Life Sciences (NASDAQ:ATAI), told Twitter that he bought 1 million shares of his company. “Many #biotech stocks are cheap at the moment. In my opinion, Atai Life Sciences AG stands out though for two reasons: the size of the market (unfortunately) the fact…

Benzinga

These 3 Psychedelic Stocks Will Benefit When The FDA Green-Lights MDMA (Molly, Ecstasy)

What Happened: According to the Multidisciplinary Association of Psychedelic Studies (MAPS), a non-profit organization, the FDA is close to greenlighting MDMA as a treatment for PTSD. MAPS reported positive results from a phase-3 trial testing the efficacy of MDMA-assisted therapy.

Benzinga

Psyched: Atai, MindMed, Enveric and Mydecine Release 2021 Earnings, Bienstar Expands To Brazil & More!

It’s earnings week in the psychedelics space, opening a new window into the financial situations of many companies in the sector.

Benzinga

atai Life Sciences Announces Fourth Quarter and Full Year 2021 Financial Results

atai Life Sciences N.V. (NASDAQ:ATAI) has announced its financial results for the fourth quarter and full year ended December 31, 2021. 2021 Financial Results Highlights included: Positive Phase 2b data with COMP360 from a ground-breaking treatment-resistant depression (TRD) trial, highly encouraging Phase 2a proof-of-mechanism data with RL-007 in cognitive impairment…

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.